Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STDS - Short Term Target of $8.75 -- Ignore unavailable to you. Want to Upgrade?

To: Andre Daedone who wrote (13)	5/6/1998 8:36:00 AM
From: Todd Frank	Read Replies (1) \| Respond to of 15

Andre: Thank you for your post. Looking at Gilbert & Chatterton report on STDS, EPS is as followed 98=.07, 99=.30, and 2000=.76. They feel this is conservative multiple of 30 times estimated earnings. They compare STDS with TWLB, RXSD, and NBTY and how they have done this past year. They feel with next year earnings that the stock can trade at 9 and at 21 in two years. I feel there is a huge market in the vitamin and supplement field with more and more doctors prescribing supplements. I don't think it is to late to climb aboard and hold this stock for the next 18 - 24 months.